IPCA Laboratories

IPCA Laboratories FCF/Debt

The Free Cash Flow to Debt Ratio of IPCA Laboratories (IPCALAB.NS) as of Oct 28, 2026 is 445.40 %. In the previous year, Free Cash Flow to Debt Ratio was 50.10 % — a change of 789.08% (higher).

FCF/Debt

445.40 %

YoY

789.08%

Last updated:

Free Cash Flow to Debt Ratio of IPCA Laboratories is 2026 445.40 % . Free Cash Flow to Debt Ratio of IPCA Laboratories was 2025 50.10 % . It decreases by 789.08% higher compared to the previous year.

The IPCA Laboratories FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2019
91.43 INR
Jan 1, 2020
61.85 INR
Jan 1, 2021
375.58 INR
Jan 1, 2022
48.69 INR
Jan 1, 2023
23.40 INR
Jan 1, 2024
51.70 INR
Jan 1, 2025
50.10 INR
Jan 1, 2026
445.40 INR
The IPCA Laboratories FCF/Debt history
YEARFCF/DebtYoY
445.40 %+789.08%
50.10 %-3.10%
51.70 %+120.97%
23.40 %-51.95%
48.69 %-87.04%
375.58 %+507.22%
61.85 %-32.35%
91.43 %+111.59%
43.21 %+57.02%
27.52 %-60.10%
68.97 %-575.80%
-14.50 %-191.10%
15.91 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IPCA Laboratories Stock analysis

What does IPCA Laboratories do? Ipca Laboratories Ltd. generates revenue through the manufacturing and marketing of over 350 pharmaceutical formulations and approximately 80 active pharmaceutical ingredients (APIs), including Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts, and Propranolol. The company sells its branded products such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, and Venpower in more than 100 countries globally. Its subsidiaries, Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd, and Tonira Exports Limited, support the distribution and sales of these products across international markets. The company's primary customers are healthcare providers, hospitals, and pharmacies in over 100 countries, purchasing both generic APIs and branded formulations. Manufacturing units in India produce APIs and formulations, with the firm's subsidiaries facilitating global market access. The therapeutic segments covered by its products include cardiovascular, antimalarial, and gastrointestinal treatments, among others, driven by the demand for cost-effective pharmaceutical solutions. IPCA Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IPCA Laboratories stock

Free Cash Flow to Debt Ratio of IPCA Laboratories is 445.40 % in 2026.

Free Cash Flow to Debt Ratio of IPCA Laboratories changed from 50.10 % to 445.40 %, representing a 789.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio IPCA Laboratories since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's IPCA Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — IPCA Laboratories

All Key Metrics — IPCA Laboratories